Technical Analysis for STML - Stemline Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 9.91 4.54% 0.43
STML closed up 4.54 percent on Friday, November 15, 2019, on approximately normal volume. It ran into resistance at its 50 day moving average.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical STML trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
50 DMA Resistance Bearish 0.00%
Multiple of Ten Bearish Other 0.00%
Calm After Storm Range Contraction 4.54%
NR7 Range Contraction 4.54%
Down 3 Days in a Row Weakness 4.54%
MACD Bearish Signal Line Cross Bearish 4.43%
Calm After Storm Range Contraction 4.43%
20 DMA Resistance Bearish 3.23%
MACD Bearish Centerline Cross Bearish 3.23%

Older signals for STML ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing proprietary therapeutics that target cancer stem cells (CSCs) and tumor bulk. It develops StemScreen platform technology consisting of StemScreen-1 and StemScreen-2 for the identification of novel CSC-directed compounds. The company is developing SL-401, a biologic-drug conjugate, which has completed Phase I/II clinical trial for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine that has completed two Phase I/II clinical trials for pediatric and adult high-grade gliomas. Its products under preclinical stage include SL-301, a small molecule gamma-secretase inhibitor that inhibits Notch, a pathway expressed by CSCs and tumor bulk of multiple cancer types; SL-101, a mAb-based compound that targets CD123; SL-201, a small molecule active against certain hematologic and solid tumor types; and SL-601, mAb-based compound that targets a cell surface marker on bladder CSCs. The company also in-licensed intellectual property directed to mAb-based therapeutics to validated oncology targets, including Glypican-3, Tie-1, CD133, Frizzled, Smoothened, and Patched. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.
Biopharmaceutical Cancer Biology Stem Cells Tumor Platform Technology Refractory Acute Myeloid Leukemia Carcinogenesis Cancer Stem Cell Cancer Stem Cells
Is STML a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 18.22
52 Week Low 7.82
Average Volume 651,287
200-Day Moving Average 12.6929
50-Day Moving Average 10.0293
20-Day Moving Average 9.9218
10-Day Moving Average 10.0105
Average True Range 0.5934
ADX 22.73
+DI 18.4177
-DI 24.4365
Chandelier Exit (Long, 3 ATRs ) 9.3448
Chandelier Exit (Short, 3 ATRs ) 10.490200000000001
Upper Bollinger Band 10.9163
Lower Bollinger Band 8.9273
Percent B (%b) 0.49
BandWidth 20.046766
MACD Line -0.0738
MACD Signal Line -0.0536
MACD Histogram -0.0201
Fundamentals Value
Market Cap 232.44 Million
Num Shares 23.5 Million
EPS -2.47
Price-to-Earnings (P/E) Ratio -4.01
Price-to-Sales 202.21
Price-to-Book 3.03
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 10.93
Resistance 3 (R3) 10.89 10.50 10.76
Resistance 2 (R2) 10.50 10.24 10.53 10.70
Resistance 1 (R1) 10.21 10.08 10.36 10.25 10.65
Pivot Point 9.82 9.82 9.90 9.85 9.82
Support 1 (S1) 9.53 9.56 9.68 9.57 9.17
Support 2 (S2) 9.14 9.40 9.17 9.12
Support 3 (S3) 8.85 9.14 9.06
Support 4 (S4) 8.89